Prof. Dr. Maximino Redondo | Health Professions | Best Scholar Award
Prof. Dr. Maximino Redondo, Universidad de Málaga, Spain
Dr. Maximino Redondo Bautista is an accomplished Spanish physician and professor, with an extensive career in clinical laboratory medicine and health research. Since 1993, he has served as a Medical Specialist at Hospital Universitario Costa del Sol in Málaga, while concurrently advancing academia as a full-time professor at the University of Málaga. With six recognized research sexennia and leadership of the hospital’s Research Unit, Dr. Redondo has made significant strides in translational medicine, oncology, and chronic disease studies. He has led 18 competitive research projects supported by the Instituto de Salud Carlos III and regional health bodies. His international collaborations and contributions to multicenter studies have shaped evidence-based healthcare practices in Spain. Through consistent involvement in national research networks like REDISSEC and RICAPPS, he promotes innovation, training, and the implementation of real-world healthcare solutions.
Profile
🌟 Assessment of Suitability for the Research for Best Scholar Award: Dr. Maximino Redondo Bautista
Summary of Suitability:
Dr. Maximino Redondo Bautista stands as a highly qualified candidate for the Research for Best Scholar Award, bringing decades of academic, clinical, and research excellence to the forefront. With a strong dual appointment as a Medical Specialist at the Hospital Universitario Costa del Sol since 1993 and a Full Professor (Catedrático) at the University of Málaga since 2023, his contributions straddle both advanced medical practice and academic leadership.
Dr. Redondo earned his Doctorate in Medicine and Surgery from the University of Granada in 1991, along with specialized academic training in Epidemiology and Clinical Research. His professional journey reflects a consistent climb, with long-term involvement in academia and research, having held multiple professorial roles and received continuous competitive research funding. Over the years, he has served as Principal Investigator in 18 competitive research projects funded by the Instituto de Salud Carlos III and the Andalusian Health Council.
🎓 Education
Dr. Redondo holds a Doctorate in Medicine and Surgery from the University of Granada (1991), which laid the groundwork for his specialization in clinical analysis and translational medical research. He also earned a University Expert Degree in Epidemiology and Clinical Research from the same university in 2000. His academic journey began with a residency (MIR) in Clinical Analysis at the University Hospital Virgen de las Nieves (1986–1990), followed by key professional training in top Spanish medical centers. Over the years, he has cultivated a strong background in biomedical sciences and public health, supported by further academic certification and participation in national programs. His extensive formal education, complemented by teaching roles since 1992, has empowered him to nurture emerging scientists, shape academic curricula, and contribute to policy-oriented research in health sciences.
💼 Professional Experience
Dr. Maximino Redondo has more than three decades of experience in clinical medicine, research, and higher education. Since 1993, he has worked as a Clinical Laboratory Specialist at Hospital Universitario Costa del Sol. In academia, he has been a professor at the University of Málaga since 1992, most recently serving as Chair Professor in the Department of Surgical Specialties, Biochemistry, and Immunology. He also served as a Tenured Professor and Associate Professor over the years. His extensive career includes significant research leadership: serving on competitive programs at Instituto de Salud Carlos III and the Andalusian Health Council. He coordinates national research networks, leads clinical studies, and contributes to translational research initiatives. Dr. Redondo’s integrated professional approach bridges patient care, scientific inquiry, and academic excellence, shaping policy and fostering innovation in health service delivery.
🏅 Awards and Recognition
Dr. Redondo has been widely recognized for his exceptional contributions to biomedical research, health policy, and academic mentorship. His work has earned six officially recognized sexenios de investigación (six-year research productivity periods), a distinguished mark in Spanish academia. He has led 18 competitive research projects and was repeatedly selected for national Intensification Programs by both Instituto de Salud Carlos III and the Andalusian Ministry of Health. Dr. Redondo played a central role in the REDISSEC and RICAPPS research networks, coordinating multicenter studies and leading national healthcare strategies. His efforts have translated research findings into impactful healthcare practices and evidence-based policy reforms. As a principal investigator and mentor, he has contributed to researcher training programs and advanced Spain’s health system through innovation and collaborative research. His influence spans medical education, diagnostics, and national public health frameworks.
🌍 Research Skills On Health Professions
Dr. Redondo excels in translational research, clinical epidemiology, biostatistics, and health services evaluation. His primary focus lies in oncology, chronic illness management, and the integration of research findings into real-world clinical practice. His skillset includes designing multicenter studies, applying evidence-based medicine, and leveraging laboratory diagnostics to inform health policies. As a senior researcher and group leader in the RICAPPS (RD21/0016/0015 and RD24/0005/0016) and REDISSEC networks, he coordinates collaborative research among hospitals, universities, and institutes across Spain. He also mentors early-career researchers, promotes interdisciplinary partnerships, and strengthens knowledge translation in healthcare. His ability to secure competitive funding and lead innovative health projects demonstrates scientific and managerial expertise. Dr. Redondo also contributes to editorial, evaluation, and strategic committees, ensuring the long-term sustainability and impact of research initiatives aimed at improving public health outcomes.
Publication Top Notes
-
🔬 Overexpression of clusterin in human breast carcinoma
Authors: M. Redondo, E. Villar, J. Torres-Muñoz, T. Tellez, M. Morell, C.K. Petito
Citation: The American Journal of Pathology, 157(2), 393–399.
Year: 2000 -
🧪 Immunotherapy: a challenge of breast cancer treatment
Authors: M. García-Aranda, M. Redondo
Citation: Cancers, 11(12), 1822.
Year: 2019 -
🧫 Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia
Authors: C. Marchal, M. Redondo, M. Padilla, J. Caballero, I. Rodrigo, J. Garcia, et al.
Citation: Histology and Histopathology, 2004.
Year: 2004 -
🧠 Deletion of lysophosphatidic acid receptor LPA1 reduces neurogenesis in the mouse dentate gyrus
Authors: E. Matas-Rico, B. Garcia-Diaz, P. Llebrez-Zayas, D. López-Barroso, L. Santin, M. Redondo, et al.
Citation: Molecular and Cellular Neuroscience, 39(3), 342–355.
Year: 2008 -
💉 Bcl-2 inhibition to overcome resistance to chemo- and immunotherapy
Authors: M. García-Aranda, E. Pérez-Ruiz, M. Redondo
Citation: International Journal of Molecular Sciences, 19(12), 3950.
Year: 2018 -
🧬 Presence of HPV 16 sequences in laryngeal carcinomas
Authors: M. Perez-Ayala, F. Ruiz-Cabello, F. Esteban, A. Concha, M. Redondo, et al.
Citation: International Journal of Cancer, 46(1), 8–11.
Year: 1990 -
🧻 The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs
Authors: M. Muñoz, R. Coveñas, F. Esteban, M. Redondo
Citation: Journal of Biosciences, 40, 441–463.
Year: 2015 -
🫁 Expression of HLA class I and II antigens in bronchogenic carcinomas: its relationship to cellular DNA content and clinical-pathological parameters
Authors: M. Redondo, A. Concha, R. Oldiviela, A. Cueto, A. Gonzalez, F. Garrido, et al.
Citation: Cancer Research, 51(18), 4948–4954.
Year: 1991 -
🔬 NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2
Authors: M. Muñoz, M. Rosso, F.J. Aguilar, M.A. González-Moles, M. Redondo, et al.
Citation: Investigational New Drugs, 26, 111–118.
Year: 2008 -
🎯 Protein kinase targets in breast cancer
Authors: M. García-Aranda, M. Redondo
Citation: International Journal of Molecular Sciences, 18(12), 2543.
Year: 2017